full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
https://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for November, 2014

25
Nov

Five years after the FDA formally rejected J&J’s Yondelis (trabectedin) for ovarian cancer, and three years after an aborted effort to get it back on track, the pharma giant has finally made its way back to the agency for another try at an approval–this time as a treatment for soft tissue sarcoma. …read more Source: […]

25
Nov

Will they or won’t they? That question seems to be on quite a few minds these days as the oddsmakers assess the chances of another Pfizer megamerger bid for AstraZeneca after the U.K.’s cooling off period ends on Wednesday. …read more Source: What are the odds? Pfizer-AstraZeneca merger chatter heats up     

24
Nov

High profile U.K. investor Neil Woodford made headlines last week when he invested $25 million into Northwest Biotherapeutics, and that’s a sign of much more to come, according to reports, as the ex-Invesco manager is planning to unveil a new fund devoted solely to emerging biotechs. …read more Source: Report: Woodford is diving full on […]

24
Nov

Amgen is calling off all clinical studies on rilotumumab in advanced gastric cancer after a peek at Phase III data revealed that the drug was actually making matters worse for patients, further marring the value of the company’s oncology pipeline. …read more Source: Amgen bails on a cancer contender that backfired in Phase III     

21
Nov

Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca’s pipeline is now nearly 50% biologics, leading the company to lay out $200 million to build the capacity it will need to follow through on those in-development projects. …read more Source: AstraZeneca earmarks $200M to support its burgeoning biologics pipeline     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off